BidaskClub upgraded shares of TherapeuticsMD (NASDAQ:TXMD) from a sell rating to a hold rating in a research note published on Friday morning.

A number of other equities research analysts also recently weighed in on the stock. Oppenheimer set a $12.00 price target on shares of TherapeuticsMD and gave the company a buy rating in a research report on Sunday, August 5th. Zacks Investment Research downgraded shares of TherapeuticsMD from a hold rating to a sell rating in a research report on Friday, August 17th. Cantor Fitzgerald lifted their price target on shares of TherapeuticsMD from $26.00 to $27.00 and gave the company an overweight rating in a research report on Tuesday, August 14th. ValuEngine downgraded shares of TherapeuticsMD from a buy rating to a hold rating in a research report on Saturday, July 28th. Finally, JPMorgan Chase & Co. started coverage on shares of TherapeuticsMD in a research report on Friday, June 15th. They issued an overweight rating and a $11.00 price target for the company. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $14.00.

TXMD stock traded down $0.09 during mid-day trading on Friday, hitting $6.15. 1,967,155 shares of the company were exchanged, compared to its average volume of 2,351,617. The company has a quick ratio of 7.79, a current ratio of 7.88 and a debt-to-equity ratio of 0.94. The company has a market capitalization of $1.44 billion, a PE ratio of -16.62 and a beta of 1.55. TherapeuticsMD has a 1-year low of $4.34 and a 1-year high of $7.66.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Monday, July 30th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.03). TherapeuticsMD had a negative return on equity of 80.75% and a negative net margin of 582.86%. The company had revenue of $3.80 million for the quarter, compared to analyst estimates of $4.23 million. During the same quarter last year, the business earned ($0.10) earnings per share. The company’s revenue was down 11.6% on a year-over-year basis. research analysts expect that TherapeuticsMD will post -0.63 EPS for the current year.

A number of large investors have recently made changes to their positions in the stock. BlackRock Inc. increased its stake in TherapeuticsMD by 4.4% in the second quarter. BlackRock Inc. now owns 14,533,524 shares of the company’s stock valued at $90,690,000 after acquiring an additional 608,470 shares during the last quarter. Voya Investment Management LLC increased its stake in TherapeuticsMD by 7.7% in the second quarter. Voya Investment Management LLC now owns 3,419,174 shares of the company’s stock valued at $21,336,000 after acquiring an additional 242,995 shares during the last quarter. OppenheimerFunds Inc. increased its stake in TherapeuticsMD by 17.4% in the second quarter. OppenheimerFunds Inc. now owns 1,932,439 shares of the company’s stock valued at $12,058,000 after acquiring an additional 286,123 shares during the last quarter. Stifel Financial Corp increased its stake in TherapeuticsMD by 1.3% in the first quarter. Stifel Financial Corp now owns 1,862,644 shares of the company’s stock valued at $9,067,000 after acquiring an additional 23,141 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado increased its stake in TherapeuticsMD by 2,545.7% in the second quarter. Public Employees Retirement Association of Colorado now owns 1,071,500 shares of the company’s stock valued at $6,686,000 after acquiring an additional 1,031,000 shares during the last quarter. 66.14% of the stock is currently owned by institutional investors and hedge funds.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Featured Story: Risk Tolerance

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.